Natera (NASDAQ:NTRA – Get Free Report) had its price objective lifted by equities researchers at Piper Sandler from $249.00 to $363.50 in a research note issued on Wednesday,Benzinga reports. Finally, UBS Group set a $260.00 target price on Natera in a research report on Wednesday, June 24th. The medical research company reported ($0.47) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.02. Also, CEO Steven Leonard Chapman sold 3,076 shares of Natera stock in a transaction that occurred on Monday, August 3rd. Natera Company Profile(Get Free Report)Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications.